Logo

Synthego Modified Synthetic sgRNA Libraries for Arrayed Whole Genome CRISPR Screening

Jul 28, 2017

Synthego announced the availability of modified synthetic single guide RNA (sgRNA) libraries for arrayed whole human genome CRISPR screening. The arrayed libraries are delivered ready-to-screen and have comprehensive coverage of the human genome, with several guide RNAs selected per gene, using the latest algorithms to enhance knockout efficiency. This leads to superior screening capabilities over RNAi and CRISPR pooled libraries, enabling a better understanding of gene function and smarter identification of drug targets for complex diseases, the company said. The Synthego whole human genome library is available in gene families including the druggable genome, transcription factors, G-protein coupled receptors, kinases, and immunology and immuno-oncology targets, among others. This feature enables focused CRISPR screens, allowing hypothesis-driven gene targeting and running of simultaneous screens without overlap.

For a full list of the gene families visit: www.synthego.com/libraries

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.